Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Vasomotor Symptoms, Hot Flashes
Interventions: RAD1901, Placebo; Drug · Other
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy
Interventions: HPG1860; Drug
Lead sponsor: Hepagene (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pharmacokinetics
Interventions: Nafamostat Mesilate, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Liver Transplantation
Interventions: MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Detroit, Michigan + 5 more

Conditions: Type 2 Diabetes Mellitus
Interventions: RO7795081, Semaglutide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Torrance, California + 15 more

Conditions: Falls
Interventions: Pharmaceutical Care, Written Materials; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bronchopulmonary Dysplasia
Interventions: Cream Supplement group; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 14 Days
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 7
States / cities: Orlando, Florida • East Lansing, Michigan • Boardman, Ohio + 4 more

Conditions: Healthy Adult Participants
Interventions: ARN-75039 oral capsules, Placebo; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Atopic Dermatitis
Interventions: APG777, Placebo; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: Fountain Valley, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Combination 5-azacytidine and nivolumab, Nivolumab; Drug
Lead sponsor: Barbara Burtness; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions: Naltrexone, Sugar Pill; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions: RSV Vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 65 Years and older
Enrollment: 5,815 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more

Conditions: Contact Lens Wear
Interventions: ASP-57, ReNu® Multiplus; Device
Lead sponsor: Asepticys LLC; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 14
States / cities: Irvine, California • San Diego, California • Longwood, Florida + 11 more

Conditions: Pancreatic Neoplasms, Periampullary Carcinoma
Interventions: Exercise, Nutritional, Behavioral Medicine, Smoking Cessation; Other · Dietary Supplement · Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 59
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more

Conditions: Head and Neck Cancer, Pain, Postoperative
Interventions: Pregabalin 150mg, Placebo; Drug · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions: Cinacalcet, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Pain
Interventions: Mindfulness Training, Book Listening Control; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Feeding Disorders
Interventions: Extremely thick blenderized tube feed, Mildly thick blenderized tube feed; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic Stem Cell Transplant, Pediatric Cancer, Deconditioning
Interventions: Exercise regimen; Behavioral
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 4 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Pain, Postoperative
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Dave Bernholt; Other
Eligibility: 14 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Skokie, Illinois • St Louis, Missouri • Durham, North Carolina + 3 more

Conditions: Non Small Cell Lung Cancer
Interventions: Talactoferrin, Placebo; Drug
Lead sponsor: Agennix; Industry
Eligibility: 18 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 29
States / cities: Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

Oral Nafamostat in Healthy Volunteers (NAF-101)

Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Preventing Falls Through Enhanced Pharmaceutical Care

Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

A Study Evaluating APG777 in Atopic Dermatitis

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

A Safety and Effectiveness Study of a New Multi-Purpose Contact Lens Care Solution

Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Brain Mechanisms Supporting Meditation-based Analgesia

Clinical Trial of Blenderized Tube Feeds Varying in Viscosity

Benefits of Intrahospital Exercise Program in Pediatric HSCT

Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer